Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
 
 
Daniel Peter Petrylak, Xin Gao, Nicholas J. Vogelzang, et al.
 
The abstract concludes: 
To date, ARV-110 has an acceptable safety profile. Concurrent ROS is now prohibited. MTD has not yet been established; determination of RP2D continues. ARV-110 demonstrates antitumor activity in mCRPC after ENZ/ABI with 2 ongoing confirmed PSA responses, one of which was associated with tumor reduction. Updated data for this first PROTAC in clinical testing will be presented. Clinical trial information: NCT03888612.

--------------------------------------------------------------------------------------------------------------------------------------------------------

3501 Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.
 
Neha Mehta-Shah, Julio C. Chavez, Pau Abrisqueta, et al.
 
The abstract concludes: 
Avadomide plus R-CHOP was well-tolerated with no significant additive toxicities. The promising efficacy in this high-risk pt population warrants further evaluation of immunomodulatory drugs combined with immunochemotherapy for pts with previously untreated DLBCL. Clinical trial information: NCT03283202.

------------------------------------------------------------------------------------------------------------------------------------------------------

3502 CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

Melissa Lynne Johnson, Anthony B. El-Khoueiry, Navid Hafez, et al.
 
The abstract concludes: 
The observed safety profile for CX-2029 effectively reduces on-target toxicity for this previously undruggable target, supporting the PROBODY platform. Evidence of anti-tumor activity was observed. Dose escalation continues. Clinical trial information: NCT03543813.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Jeeyun Lee, Seung KIM, Dr Simon Smith, et al.
 
The abstract concludes: 
We conclude that AZD6738 can be safely combined with weekly paclitaxel and propose a recommended phase II dose and schedule. The combination of AZD6738 and paclitaxel demonstrated promising anti-tumor activity with durable responses, especially in melanoma pts after failing anti-PD1 therapy. Clinical trial information: NCT02630199.
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Johanna C. Bendell, James Fredric Strauss, Marwan Fakih, et al. 
 
The abstract concludes: 
Among 17 patients treated with single agent therapy, no DLTs occurred; notably, exposures predicted to be sufficient to inhibit human tumor growth from preclinical models were achieved along with concomitant pharmacodynamic effects. These data, along with a durable PR observed in the highest dose cohort, support further development of RGX-202. Consequently, dose escalation in combination with FOLFIRI in patients with advanced GI cancers is underway with plans for expansion in CKB+ CRC pts. Clinical trial information: NCT03597581.

-------------------------------------------------------------------------------------------------------------------------------------------------------

3505 Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial.

Olivier Rixe, John Charles Morris, Robert Wesolowski, et al. 
 
The abstract concludes: 
BXQ-350 was well tolerated with no significant dose-limiting toxicities at the highest planed dose level. Preliminary results indicate this novel agent demonstrated possible anti-tumor activity in refractory solid tumors and HGG. Clinical trial information: NCT03967093).
--------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, et al.
 
The abstract concludes: 
Copanlisib showed meaningful clinical activity across various tumors with PIK3CA mutation in the late-line refractory setting. Further study either alone or in combinations in select tumors is warranted. G3/4 toxicities observed were consistent with reported toxicities for PI3K pathway inhibition. Clinical trial information: NCT02465060.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Benedito A. Carneiro, Ludimila Cavalcante, Bruno R. Bastos, et al. 
 
The abstract concludes: 
9-ING-41 has dose-proportional PK, is well tolerated with significant antitumor activity as monotherapy and in combination with chemotherapy in pts with refractory tumors. 1 ongoing CR was observed in a refractory BRAF-mutated melanoma. A biologically active dose has been reached, although MTD has not been determined. Enrollment is ongoing. Clinical trial information: NCT03678883.